Fig. 4: Stable nuclear accumulation of the WUS protein (pWUS::eGFP-WUS) in the L1 layer of clv3-2 mutants upon Leptomycin-B treatments. | Nature Communications

Fig. 4: Stable nuclear accumulation of the WUS protein (pWUS::eGFP-WUS) in the L1 layer of clv3-2 mutants upon Leptomycin-B treatments.

From: CLAVATA3 mediated simultaneous control of transcriptional and post-translational processes provides robustness to the WUSCHEL gradient

Fig. 4

a, b Wild-type plants with pWUS::eGFP-WUS reporter in response to a mock (n = 5) or b 20 nM LEP-B (n = 6) treatments. c Quantification of pWUS::eGFP-WUS fluorescence levels (mean ± s.d.) from treatments shown in a, b. The “n” represents the number of independently treated plants. d, e clv3-2 mutant plants with pWUS::eGFP-WUS reporter in response to d mock (n = 6) or e 20 nM LEP-B (n = 5) treatments for 24 h. f Quantification of pWUS:: eGFP-WUS fluorescence levels (mean ± s.d.) from treatments shown in d, e. The “n” represents the number of independently treated plants. The * represents a p value ≤ 0.05 when compared to WUS levels from mock treatments in the same cell layer (Student’s two-tailed t-test). Error bars represent the standard deviation. eGFP (green) is overlaid on FM4-64 (Red) plasma membrane stain. Scale bars = 20 μM.

Back to article page